Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
REGN-5668 by Regeneron Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
REGN-5668 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...